Strategic partnership LatinaBA recently formed a strategic collaboration with P95 to boost vaccine and infectious disease research in Latin America, signaling a potential for joint-denial co-development opportunities, regional expansion, and shared funding or grant access.

Infectious disease focus Strong emphasis on infectious diseases including Chagas, HIV, Hepatitis, influenza, and vaccines suggests opportunities to cross-sell clinical operations, regulatory support, and multi-country trial management services to biotechs and pharma expanding Latin American programs.

Clinical expertise breadth Experience spans perinatal, pediatric, gene therapy, medical devices, orphan indications, and a wide CNS, oncology, and immunology portfolio, enabling LatinaBA to position as a versatile CRO/CMO partner for specialized trials and complex study designs.

Regulatory and ethics exposure Participation in ethical clinical research forums and regulatory affairs capability indicate readiness to assist sponsors navigating Latin American regulatory landscapes, site qualification, and compliance, reducing time-to-trial in new markets.

Growth and visibility Revenue range and active senior management with a regional country management structure imply scalable operations and potential for broader outreach to global sponsors seeking LATAM trial access, particularly in vaccines, rare diseases, and gene therapy.